Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma

Mod Pathol. 2001 Nov;14(11):1147-56. doi: 10.1038/modpathol.3880450.

Abstract

Angiotropic lymphoma (AL) is an uncommon lymphoma often presenting with nonspecific clinical features and having a high mortality rate. Although not specifically recognized by the Revised European-American Classification of Lymphoid Neoplasms, it likely will appear as a subtype of diffuse large B-cell lymphoma in the upcoming WHO classification. Some authors may also consider it to be a subtype of cutaneous lymphomas. Recent studies have reported an immunophenotypic heterogeneity of AL, and in rare instances, an association with other NHL. To further characterize AL, we studied the immunophenotype by immunohistochemistry for CD5, CD10, CD20, bcl-2, and bcl-6 in 18 cases of B-cell AL identified at three medical centers in North America. Bcl-2 gene rearrangement status by polymerase chain reaction and Epstein Barr virus status by in situ hybridization also were evaluated. Eight men and 10 women were identified with AL (median age 71 years). Eleven patients were diagnosed in life and seven were diagnosed at autopsy. Neurologic symptoms were the most common presentation, seen in six patients. Skin was the most commonly biopsied site. All showed classic intravascular localization; in two cases, there was also a minor diffuse large cell lymphoma component observed in some organs. Most (89%) of the cases expressed bcl-2 protein; CD10, bcl-6 and CD5 were each expressed in 22% of cases. Based on CD5 and CD10 expression, three major groups were evident: CD5-, CD10- (11 cases); CD5+, CD10- (3 cases), and CD5-, CD10+ (3 cases). Even though a follicle center lymphoma preceded the AL in one patient, we did not detect bcl-2 gene rearrangement in any of these cases. All cases were negative for Epstein Barr virus. Of the five treated with chemotherapy, two achieved a complete remission. Based on these findings, we conclude that ALs are clinically and immunophenotypically heterogeneous and may represent more than one pathogenetic entity. In some instances AL may be preceded by another lymphoproliferative disorder, raising the possibility that some cases of AL may represent a transformation from another type of lymphoma. Cutaneous manifestations of AL are common; however, it appears to be a systemic lymphoma. Although often fatal, patients with AL who are diagnosed early and treated with chemotherapy may achieve remission.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, CD / analysis
  • Antigens, CD20 / analysis
  • CD5 Antigens / analysis
  • CD79 Antigens
  • Chromosomes, Human, Pair 14 / genetics
  • Chromosomes, Human, Pair 18 / genetics
  • DNA, Neoplasm / genetics
  • DNA-Binding Proteins / analysis
  • Female
  • Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics
  • Humans
  • Immunohistochemistry
  • Leukocyte Common Antigens / analysis
  • Lymphoma, B-Cell / genetics
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / pathology*
  • Male
  • Middle Aged
  • Neprilysin / analysis
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-6
  • Receptors, Antigen, B-Cell / analysis
  • Transcription Factors / analysis
  • Translocation, Genetic
  • Vascular Neoplasms / genetics
  • Vascular Neoplasms / metabolism
  • Vascular Neoplasms / pathology*

Substances

  • Antigens, CD
  • Antigens, CD20
  • CD5 Antigens
  • CD79 Antigens
  • CD79A protein, human
  • DNA, Neoplasm
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-bcl-6
  • Receptors, Antigen, B-Cell
  • Transcription Factors
  • Leukocyte Common Antigens
  • Neprilysin